Healthy subjects
Conditions
Interventions
Continuous intake of the test food for 12 weeks
Continuous intake of the test food for 12 weeks
Sponsors
HUMA R&D CORP
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Japanese males and females who are between 40 and 69 years of age at the time of written informed consent. 2. Subjects who are aware of cognitive decline. 3.Subjects whose scoring of MMSE-J is 24 or more at screening. 4.Subjects who have a "yes" in the validity indicator of Cognitrax on both verbal memory and visual memory at screening. 5.Subjects who have relatively low standardized score in composite memory measured using Cognitrax at screening. 6.Subjects who are fully explained the purpose and details of the study, have ability to consent, are volunteering to participate in the study with a full understanding of the explanation, and have consented to participate in the study in writing.
Exclusion criteria
Exclusion criteria: 1.Subjects who have been diagnosed with dementia by a physician. 2.Subjects receiving medication or outpatient treatment for a serious disease. 3.Subjects receiving exercise or diet therapy under the supervision of a physician. 4.Subjects who may develop an allergy to the ingredient of the test food (rosemary) or aspirin. 5.Subjects with current or previous history of drug dependence or alcohol dependence. 6.Subjects who are currently seeing a doctor for the treatment of a psychiatric disorder (e.g., depression) and/or sleep disorder (e.g., insomnia, sleep apnea syndrome) or have previous history of a psychiatric disorder. 7.Subjects who have extremely irregular life rhythms due to night work, shift work, etc. 8.Subjects whose eating, sleeping, and other habits are extremely irregular. 9.Subjects who are having a very unbalanced diet. 10.Heavy users of alcohol (the mean consumption of pure alcohol is 60 g/day or more) or excessive smokers (21 cigarettes/day or more). 11.Subjects with current or previous history of a brain disease, malignancy, immunological disease, diabetes mellitus, hepatic disease (hepatitis), renal disease, cardiac disease, thyroid disease, adrenal disease, metabolic disease, or other serious diseases. 12.Subjects who use or are unable to stop using health foods, supplements (e.g., DHA, EPA, ginkgo biloba extract, tocotrienol, astaxanthin, GABA, phosphatidylserine, and plasmalogen), and drugs that may affect cognitive functioning. 13.Subjects with color blindness. 14.Subjects who usually use devices, equipment, and applications that may affect cognitive functions. (e.g., brain training puzzles, brain training games) 15.Subjects who participated in another clinical study/research within 3 months before the date of informed consent or who plan to participate in another clinical study/research during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitrax (standardized score for "comprehensive memory") | — |
Secondary
| Measure | Time frame |
|---|---|
| (Secondary outcomes) Cognitrax (standardized scores except for "comprehensive memory") (Safety evaluation) Vital signs, physical measurements (body weight and BMI), biochemical test, hematology test, urinalysis, adverse events | — |
Countries
Japan
Contacts
Public ContactHiroyuki Miyazawa
HUMA R&D CORP Clinical Development Department
Outcome results
None listed